No Data
Hong Kong Stock Announcement Gold Mining | Bosideng (03998) announces mid-term performance, the profit attributable to equity shareholders rose by 23% year-on-year to approximately 1.13 billion yuan.
Dianzhi (02586) will conduct IPO from November 28th to December 3rd, planning to globally issue 25.774 million shares; Reshaping Energy (02570) will conduct IPO from November 28th to December 3rd, planning to globally issue approximately 4.8279 million shares.
Express News | New Indication of Olverembatinib Included Into China 2024 National Reimbursement Drug List
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Asia Sheng Pharmaceutical appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors.
Rockville, Maryland and Suzhou, china, November 25, 2024 /PR Newswire/ -- As a leading biomedical company dedicated to developing innovative drugs in areas such as oncology, Ascletis Pharma (6855.HK) announced today the appointment of Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors of the company, effective November 25, 2024. Dr. Yang Dajun, chairman and CEO of Ascletis Pharma, stated: "We warmly welcome Ms. Marina S. Bozilenko and
Talnix BIC's potential recognized by international authoritative journals again, Aegis Medicine-B(06855) milestone developments successively announced boosting market confidence.
On November 22, Ascentage Pharma announced that data from its Phase Ib overseas clinical trial (NCT04260022) on the core product Olverembatinib (trade name: Nalik) for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients has been successfully published in the November 2024 issue of JAMA Oncology, once again reflecting the high recognition of the international hematology community for Olverembatinib as a globally best-in-class potential drug.
Hong Kong stocks unusual movement | Ascentage Pharma-B (06855) up nearly 3%, surpassing the Krysa NDA CED acceptance by force, institutions point to the difficulty of becoming the first domestic drug target.
As of the time of writing, AstraZeneca Pharmaceuticals-B (06855) rose nearly 3%, with an increase of 2.67% to 42.25 Hong Kong dollars, and a turnover of 49.0676 million Hong Kong dollars.
No Data
